JP2021515039A5 - - Google Patents

Info

Publication number
JP2021515039A5
JP2021515039A5 JP2020567470A JP2020567470A JP2021515039A5 JP 2021515039 A5 JP2021515039 A5 JP 2021515039A5 JP 2020567470 A JP2020567470 A JP 2020567470A JP 2020567470 A JP2020567470 A JP 2020567470A JP 2021515039 A5 JP2021515039 A5 JP 2021515039A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
asthma
antibody
antigen
Prior art date
Application number
JP2020567470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515039A (ja
JP7572041B2 (ja
JPWO2019169015A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019872 external-priority patent/WO2019169015A1/en
Publication of JP2021515039A publication Critical patent/JP2021515039A/ja
Publication of JP2021515039A5 publication Critical patent/JP2021515039A5/ja
Publication of JPWO2019169015A5 publication Critical patent/JPWO2019169015A5/ja
Application granted granted Critical
Publication of JP7572041B2 publication Critical patent/JP7572041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567470A 2018-02-27 2019-02-27 重症喘息を処置するための組成物および方法 Active JP7572041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636092P 2018-02-27 2018-02-27
US62/636,092 2018-02-27
PCT/US2019/019872 WO2019169015A1 (en) 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma

Publications (4)

Publication Number Publication Date
JP2021515039A JP2021515039A (ja) 2021-06-17
JP2021515039A5 true JP2021515039A5 (https=) 2022-03-07
JPWO2019169015A5 JPWO2019169015A5 (https=) 2022-03-07
JP7572041B2 JP7572041B2 (ja) 2024-10-23

Family

ID=65724591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567470A Active JP7572041B2 (ja) 2018-02-27 2019-02-27 重症喘息を処置するための組成物および方法

Country Status (14)

Country Link
US (2) US20210380711A1 (https=)
EP (1) EP3759140A1 (https=)
JP (1) JP7572041B2 (https=)
KR (1) KR20200128415A (https=)
CN (1) CN112424226B (https=)
AU (1) AU2019228508A1 (https=)
BR (1) BR112020017445A2 (https=)
CA (1) CA3091920A1 (https=)
IL (1) IL276875A (https=)
MX (1) MX2020008916A (https=)
PH (1) PH12020551323A1 (https=)
SG (1) SG11202008149RA (https=)
WO (1) WO2019169015A1 (https=)
ZA (1) ZA202005320B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
AU2021392748A1 (en) * 2020-12-04 2023-06-29 Equillium, Inc. Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CA2282410A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 B-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CN102559636B (zh) * 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
JP6296650B2 (ja) 2013-03-13 2018-03-20 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用
CA2992262A1 (en) 2015-07-15 2017-01-19 Kyowa Hakko Kirin Co., Ltd. Antibody which specifically binds to human crth2
WO2017218750A1 (en) * 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Cd6のリン酸化を低減させるためのイトリズマブの使用

Similar Documents

Publication Publication Date Title
JP2021515039A5 (https=)
EP2500361B1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
EP4198055A1 (en) Antibody of il-11 and use thereof
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
US9067996B2 (en) Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN110624107A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
JP2017501711A (ja) 二重特異性抗体
JP2014511179A5 (https=)
JP2017507945A5 (https=)
HUE031923T2 (en) Antibody molecules that exhibit binding specificity for human IL-13
JP2019513726A5 (https=)
EP2986640B1 (en) Humanized antibody against interleukin-20 and treatment for inflammatory diseases
WO2020034941A1 (zh) 抗IL-1β的抗体、其药物组合物及其用途
JP2024525870A (ja) 抗pla2r自己抗体媒介膜性腎症の治療
TW202235435A (zh) 抗cd38抗體及其用途
JPWO2019169015A5 (https=)
US20260008865A1 (en) Antibodies, compositions, and methods of treatment
JPWO2023098888A5 (https=)
CN116635422A (zh) 抗cd38抗体及其用途
WO2021139687A1 (zh) 抗cd47抗体和抗cd20抗体的组合在制备用于预防或治疗肿瘤的药物中的应用
WO2023205617A1 (en) Antibodies and methods targeting interleukin-19
RU2020130563A (ru) Антитела к cd6 для лечения тяжелой астмы
NZ619873A (en) Methods and compositions for treating asthma using anti-il-13 antibodies
HK1137182B (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof